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Background: The ligand for CD137 (CD137L; also called 
4-1BBL) is mainly expressed on activated APCs such as den-
dritic cells, B cells and macrophages. Even though CD137L 
functions as a trigger of the CD137 signaling pathway for T 
cell activation and expansion, engagement of CD137L can 
deliver a signal leading to the production of proinflammatory 
cytokines in macrophages. Methods: We generated cell-per-
meable TAT-CD137L cytoplasmic domain fusion protein 
(TAT-CD137Lct) and examined its ability to initiate the 
CD137L reverse signaling pathway. Results: Treatment of 
TAT-CD137Lct induced the production of high levels of IL-6 
and TNF-α  mRNAs and proteins in peritoneal macrophages. 
TAT-CD137Lct increased phosphorylation of Erk, p38 MAPK 
and Jnk, and activated transcription factors C/EBP and 
CREB. However, TAT-CD137Lct did not visibly affect the 
degradation of the inhibitor of NF-kB (IkBα). We further 
demonstrated that JNK activation was required for 
TAT-CD137Lct-induced production of TNF-α, while activa-
tion of Erk and p38 MAPK were involved in IL-6 and TNF-α 
production.  Conclusion:  Our results suggest that TAT- 
CD137Lct is an effective activator for the CD137L reverse 
signaling pathway. 
[Immune Network 2011;11(4):216-222]
INTRODUCTION
There is evidence for the existence of reverse signaling path-
ways  of  TNF  superfamily  members  (1),  including  CD137L 
(2,3). CD137L reverse signals have been shown to mediate 
various cellular responses not only in immune cells such as 
monocytes/macrophages (4-8), dendritic cells (9,10), T cells 
(11,12), and B cells (13,14) but also in non-immune cells such 
as endothelial cells (15) and carcinoma cells (16,17). Biologi-
cal  activities  that  are  mediated  by  CD137L  reverse  signals 
have  been  characterized  most  in  details  in  monocytes/ 
macrophages. For example, engagement of CD137L in mono-
cytes/macrophages  increases  their  migration  and  proin-
flammatory  cytokine  production  (4-8,15,18,19).  In  addition, 
evidence is accumulating that CD137L signals are important 
for  myelopoiesis.  It  has  been  clearly  demonstrated  that 
CD137L signals negatively regulate myelopoiesis (20). However, 
in  vitro e x p e r i m e n t s  u s i n g  C D 1 3 7 - F c  f u s i o n  p r o t e i n  h a v e  
shown that stimulation of the CD137L signaling promotes pro-
liferation  of  hemaopoietic  progenitor  cells  and  their  differ-
entiation  into  monocytes  (21,22).
    To trigger the CD137L reverse signaling without blocking 
the CD137 receptor signaling pathway, we generated  fusion 
protein consisting of the CD137L cytoplasmic domain and the 
protein transduction domain (PTD) of HIV TAT (48-57 amino 
acid  residues:  GRKKRRQRRR)  (TAT-CD137Lct).  A  delivery 
t o ol  us in g  TA T is  wi de ly  u se d t o  mo d ul at e v ar io us  ce ll ul ar 
activities (23). We showed that the TAT-CD137Lct evoked ac-
tive CD137L reverse signaling in peritoneal macrophages. Our 
results  suggest  that  recombinant  TAT-CD137Lct  protein 
should be used as an effective activator for the CD137L re-Triggering of CD137L Signaling Using Transduced CD137L Protein
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verse signaling pathway without interfering with interactions 
between  CD137  and  CD137L. 
MATERIALS AND METHODS
Mice and reagents
C57BL/6  mice,  6-8  wk  of  age,  were  purchased  from  Hyo 
Chang Bioscience (Korea). Peritoneal macrophages were iso-
lated by peritoneal larvage with 1x PBS (WelGENE, Korea). 
Mixture containing macrophages and RBCs was incubated in 
RBC lysis buffer for 5 min on ice and washed with 1x PBS 
three  times.  After  that,  cells  were  counted  using  hemocy-
tometer  and  cultured  in  DMEM  (WelGENE)  containing  1% 
FBS (WelGENE). The following Abs were used for immuno-
blotting: Abs to p-p38, p38, p-Erk, Erk (all from Cell signaling 
Technology, Danvers, MA), IkBα (Santa Cruz Biotechnology), 
GAPDH (Millipore), and His (Santa Cruz Biotechnology, Santa 
Cruz, CA). Erk inhibitor (PD98059), p38 inhibitor (SB203580), 
and  Jnk  inhibitor  (SP600125)  were  purchased  from  Merk 
(Germany).
Plasmid constructs
Total RNA isolated using TRIzol reagent (Invitrogen, Carlsbad, 
CA) from mouse spleens was subjected to cDNA synthesis us-
ing  Olig  dT  and  AMV  reverse  transcriptase  (Promega, 
Madison,  WI).  The  cytoplasmic  domain  of  mouse  CD137L 
g e n e  w a s  a m p l i f i e d  b y  P C R  u s i n g  s e n s e  ( 5’-GAATTCATGG 
ACCAGCACACA-3’) and antisense primers (5’-CTCGAGTCAT 
GGGTGGCGGGA-3’).  CD137Lct  DNA  fragments  were  in-
serted  in  pET21a-HisTAT  vector  (TAT-CD137Lct).  To  con-
struct pET21a-HisTAT vector, double-stranded oligonucleotide 
including  his-tag  and  TAT  sequences  was  prepared  by  an-
nealing (heating at 95
oC for 5 min and chilling at room tem-
perature for 60 min) of single-strand oligonucleotides (Forward, 
5’-CAT ATG CAC CAC CAC CAC CAC CAC TAT GGC AGG 
AAG-3’; Reverse, 5’-GGA TCC TCG TCG TCG CTG TCT CCG 
CTT CTT CCT GCC-3’) and then inserted in pET21a vector. 
EGFP sequence was obtained from pEGFPN1 vector (Clonetech 
Laboratories, Mountain View, CA) by PCR amplification using 
the  following  primers:  sense,  5’- G A A  T T C  A T G  A G T  A A A  
GGA  GAA-3’;  antisense,  5’-CTC  GAG  TTT  GTA  TAG  TTC 
ATC-3’. 
Production of recombinant proteins 
BL12  star  E.  coli  (Merk,  Germany)  were  transformed  with 
each  DNA  construct,  cultured  overnight,  and  added  with  1 
mM  isopropyl-β-D-thiogalactopyranoside (IPTG) for protein 
induction at 37
oC for 6 h. Harvested cells were sonicated in 
lyisis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imida-
zole). Lysates were clarified by centrifugation at 13,000 rpm 
for 20 min at 4
oC. Clarified lysates were bound with Ni-NTA 
agarose bead (QIAGEN, Valencia, CA) for 1 h. Bound pro-
teins  were  washed  5  times  with  washing  buffer  (50  mM 
NaH2PO4, 300 mM NaCl, 50 mM imidazole ) and eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imi-
dazole).  Purified  proteins  were  dialysed  using  1x  PSB  (pH 
8.0) and LPS was removed using ToxinEsaer TM Endotoxin 
Removal  kit  (GeneScript,  Piscataway,  NY).  Protein  concen-
tration  was  measured  using  bicinchoninic  acid  (BCA)  kit 
(Thermo  Scientific,  Rockford,  IL). 
Transduction assay
Peritoneal macrophages (1×10
6) were incubated with 10 μM 
TAT-EGFP, CD137Lct, TAT-CD137Lct and TAT-CD137Lct-EGFP 
for 3 min. Cells were lysed in lysis buffer (50 mM Tris-HCl 
[pH7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM PMSF, 
protease inhibitors, 1 mM NaF, and 0.1 mM Na3VO4) on ice 
for  30  min.  Proteins  were  resolved  in  17%  SDS-PAGE  and 
transferred onto nitrocellulose membranes. Immunoblot pro-
cedure was described in the next section. Transduced pro-
teins were detected by anti-his Abs. Intracellular localization 
of TAT-EGFP and TAT-CD137Lct-EGFP protein was visualized 
by confocal microscopy. Cells were cytospinned at 1,000 rpm 
for 15 min on slide glass. Cytospinned cells were mounted 
with  Fluromount-G  solution  (Southern  Biotech).
Immunoblot
Protein lysates were prepared from peritoneal macrophages 
and their protein concentrations were determined using the 
Bio-Rad assay kit (Hercules, CA). Lysates (5  μg of protein 
per  sample)  were  mixed  with  gel  loading  buffer  (60  mM 
Tris/HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM β-mercap-
toethanol,  0.1%  bromphenol  blue)  and  boiled  for  3  min. 
Proteins were resolved in 15% or 17% SDS-PAGE and trans-
ferred to nitrocellulose membranes (Millipore, Bedford, MA). 
Membranes were blocked for 1 h in blocking buffer (1X TBST 
[50 mM Tris-HCl, pH 7.5, 150 mM NaCl] including 5% dried 
milk), followed by overnight incubation at 4
oC with first Abs. 
Membranes  were  washed  3  times  with  1X  TBST  and  in-
cubated with secondary Abs conjugated with alkaline phos-
phatase (Santa Cruz Biotechnology) for 1 h at room temper-
ature  and  developed  by  ECL-plus  substrate  kit  (Amersham Triggering of CD137L Signaling Using Transduced CD137L Protein
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Figure 1. Production and transduction of TAT
fusion proteins. (A) Plasmid constructs of the 
TAT fusion proteins. (B) Purified proteins were
separated on 13% SDS-PAGE and then stained
with Commasie blue. (C, D) Transduction 
activity of purified proteins was analyzed using
immunoblot (C) and confocal microscope (D).
Peritoneal macrophages (1×10
6) were incu-
bated with 10 μM of TAT-EGFP, CD137Lct, 
TAT-CD137Lct, and TAT-CD137Lct-EGFP for 
30 min. Transduced proteins were detected 
using anti-his Abs (C). Intracellular localization
of TAT-EGFP and TAT-CD137Lct-EGFP were 
observed using confocal microscopy (D). 
Scale bar is 10μm. 
Biosciences,  Piscataway,  NJ).
Cytokine measurement by cytometric bead array 
(CBA)
Peritoneal  macrophages  (1×10
5)  w e r e  t r e a t e d  w i t h  2 0  n g  
TAT-EGFP, CD137Lct, TAT-CD137Lct, and TAT-CD137Lct-EGFP 
for 4 h. Culture supernatants were collected and the amount 
of  IL-6  and  TNF-α was  quantified  using  a  CBA  kit  (BD 
Biosciences, San Diego, CA) with a FACS-Caliber cytometer 
equipped with Cell-QUEST-PRO and CBA software according 
t o  t h e  m a n u f a c t u r e r ’s  instructions.
RT-PCR
Total RNA isolated using TRIzol reagent (Invitrogen) was sub-
jected to cDNA synthesis using Olig dT and AMV reverse tran-
scriptase  (Promega).  Dilutions  (5-  or  10-fold)  of  cDNA  re-
action mixtures were subjected to PCR amplification using the 
following primers: IL-6 sense, 5’-GATGCTACCAAACTGGATA 
TAATC-3’; IL-6 antisense, 5’-GGTCCTTAGCCACTCCTTCTGTG-3’; 
TNF-α sense, 5’- AGGGGCCACCACGCTCTT CT-3’; TNF-α  
antisense, 5’- CGGGGCAGCCTTGTCCCTTG-3’; GAPDH sense, 
5’-TGAAGGTCGGTGTGAACGGATTTG-3’; GAPDH antisense, 
5’-CATGTAGGCCATGAGG  TCCACCAC-3’.
EMSA
Nuclear  extracts  were  prepared  from  1×10
6  of  peritoneal 
macrophages  stimulated  with  50  ng  TAT-  EGFP,  CD137Lct 
and TAT-CD137Lct proteins. Cells were washed with ice-cold 
PBS, resuspended in buffer A (20 mM HEPES, pH 7.9, 1.5 
mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 0.5 mM dithiothreitol, 
and 0.5 mM phenylmethylsulfonyl fluoride), and left on ice 
for 10 min. Nuclei were pelleted by centrifugation at 5,000 
rpm for 10 min at 4
oC and resuspended in buffer B (20 mM 
HEPES, pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 
20% glycerol, and 1 mM dithiothreitol). After incubation for 
30 min at 4
oC, the mixture was centrifuged at 13,000 rpm for 
15 min at 4
oC. The supernatant as nuclear extract was col-
lected and stored at −70
oC until use. The C/EBP (sc-2525) 
and CREB (sc-2504) probe was purchased from Santa Cruz. 
Each  probe  was  end-labeled  with  [γ-
32P]dATP  (Amersham 
Biosciences) by T4 polynucleotide kinase (Promega). The nu-
clear extracts and probe were incubated for 30 min at room 
temperature in reaction buffer containing 10 mM HEPES, pH 
7.9, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and 5% glycerol. 
Each reaction contained 0.02 unit of poly[dI-dC] (Sigma, St. 
Louis, MO). Reactions were electrophoresed on a 4% non-de-
naturing polyacrylamide gel in 0.5X Tris borate-EDTA buffer Triggering of CD137L Signaling Using Transduced CD137L Protein
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Figure 2. TAT-CD137Lct induces IL-6 and TNF production in peritoneal macrophages. (A, B) Peritoneal macrophages (1×10
5) were treated with
indicated concentrations of TAT- EGFP, CD137Lct, TAT-CD137Lct, and TAT-CD137Lct-EGFP and cultured for 4 h. Culture medium was collected
and levels of IL-6 (A) and TNF-α (B) were measured using a CBA kit. Heat-inactivated (HI) TAT-CD137Lct was used as a negative control and
LPS (10 ng/ml) and CD137-Fc (100 ng/ml) as a positive control. Data are the mean±SD of triplicates. (C) Total RNA was extracted from peritoneal
macrophages (1×10
6) that were treated with 20 ng of protein. Total RNA was subjected to cDNA synthesis. The TNF-α and IL-6 transcripts
were amplified using specific primer sets and the PCR products were analyzed using 1.5% agarose gel electrophoresis. GAPDH mRNA expression
was used as an internal control. (D) Density of amplified PCR product bands was analyzed using Image J program and normalized against the 
density of the GAPDH band.
at  150  V  for  2  h,  and  then  analyzed  by  autoradiography.
RESULTS
Purification of TAT-CD137Lct protein 
We generated DNA constructs to produce polyhistidine-tagged 
TAT-CD137Lct, CD137Lct, TAT-CD137Lct-EGFP, and TAT-EGFP 
proteins in E. coli (Fig. 1A). Recombinant proteins purified 
using Ni-NTA agarose beads had expected molecular weights 
when separated in 13% SDS-PAGE gel (Fig. 1B). Western blot 
analysis showed that all TAT fusion proteins were able to be 
permeabilized into peritoneal macrophages (Fig. 1C). Trans-
duced  TAT-CD137Lct-EGFP  was  localized  beneath  the  cell 
membrane  of  peritoneal  macrophages  and  TAT-EGFP  was 
found throughout the cytoplasm (Fig. 1D). Our results sug-
gest that TAT fusion proteins could easily penetrate into the 
cell.
TAT-CD137Lct induces IL-6 and TNF production in 
macrophages 
CD137L reverse signaling induces IL-6 and TNF-α production 
in  monocytes  (4).  We  investigated  whether  transduction  of 
TAT-CD137Lct  would  result  in  the  production  of  IL-6  and 
TNF-α in peritoneal macrophages. Peritoneal macrophages 
produced  high  levels  of  IL-6  and  TNF-α in  response  to 
TAT-CD137Lct and TAT-CD137Lct-EGFP in a dose-dependent Triggering of CD137L Signaling Using Transduced CD137L Protein
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Figure 3. TAT-CD137Lct induced phosphorylation of Erk, p38, and Jnk and activaton of C/EBP and CREB. (A) Peritoneal macrophages (1×10
6) 
were treated with 50 ng of indicated proteins and harvested at 0, 15, 30, 60, and 120 min after their treatment. Lysates (10μg) were used 
for immunoblot. LPS (50 ng/ml) is used as a positive control. p-, phosphorylated. (B, C) Peritoneal macrophages (1×10
5)  were treated with
TAT-CD137Lct (20 ng) in the presence of PD98059, SB203580, or SP600125 (10μM each) and cultured for 4 h. Levels of IL-6 (B) and TNF
(C) in culture medium were measured using a CBA kit. Data are the mean±SD of triplicates. (D) EMSA for nuclear extracts from peritoneal 
macrophages stimulated with 50 ng of indicated proteins was performed with radiolabeled C/EBP and CREB probes. LPS (50 ng/ml) is used 
as a positive control.
manner (Fig. 2A and B). A high concentration of CD137Lct 
slightly  induced  the  production  of  IL-6  and  TNF-α.  This 
might  be  due  to  the  ability  of  macrophages  to  uptake  ex-
tracellular proteins, since TAT-EGFP had no effect on the cy-
tokine production of macrophages. Heat-inactivated TAT-CD137Lct 
did not stimulate macrophages to produce IL-6 and TNF-α, 
suggesting that there was no LPS contamination. As expected, 
LPS and  CD137-Fc  (100  ng/ml) was potent  in inducing the 
production  of  IL-6  and  TNF-α in  peritoneal  macrophages. 
RT-PCR analysis showed that TAT-CD137Lct also significantly 
increased mRNA levels of IL-6 and TNF-α in peritoneal mac-
rophages  (Fig.  2C  and  D).
TAT-CD137Lct activates Erk, p38 MAPK, JNK, and 
transcription factors CREP and C/EBP
To  further  define  the  mechanism  by  which  TAT-CD137Lct 
controls macrophage production of IL-6 and TNF-α, we in-
vestigated what intracellular signaling molecules are involved 
in this process. TAT-CD137Lct increased phosphorylation of 
the kinases  Erk, p38 and JNK  but had no  visible  effect on 
the degradation rate of the inhibitor of NF-κB (IκBα) (Fig. 
3A). Consistent with  this result,  the production  of IL-6  and 
TNF-α in peritoneal macrophages was inhibited specifically 
by the Erk (PD98059) and p38 (SB203580) inhibitors (Fig. 3B 
and  C).  Interestingly,  the  JNK  inhibitor  (SP600125)  blocked 
the production of TNF-α but not IL-6 in TAT-CD137Lct- stimu-
lated macrophages. We also found that TAT-CD137Lct strong-
ly activated CREB and C/EBP in macrophages at 12 h after 
its treatment (Fig. 3D). Our data are consistent with previous 
studies  showing  that  CD137L  is  required  for  activation  of 
CREB  and  C/EBP  but  not  NF-κB  in  macrophages  (19). 
An additive effect of TAT-CD137Lct and LPS
It  has  been  shown  that  interactions  of  cell  surface  CD137L Triggering of CD137L Signaling Using Transduced CD137L Protein
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Figure 4. An additive effect of TAT-CD137Lct
and LPS. Peritoneal macrophages (1×10
5)
were treated with indicated concen-
trations of TAT-CD137Lct and LPS and 
cultured for 4 h. Culture medium was 
collected and levels of IL-6 (A) and TNF-
α (B) was measured using a CBA kit. 
with TLR4 increase LPS-induced cytokine production in mac-
rophages  (19).  Since  TAT-CD137Lct  seemed  to  evoke  the 
CD137L signaling pathway regardless of CD137L on the cell 
surface, we predicted that TAT-CD137Lct would have an ad-
ditive  effect  with  LPS  on  cytokine  production  in  macro-
phages. Indeed, co-treatment of TAT-CD137Lct and LPS showed 
an additive effect on IL-6 and TNF production in peritoneal 
macrophages  (Fig.  4). 
DISCUSSION
In this study, we generated TAT-CD137Lct fusion protein that 
could penetrate into macrophages and trigger CD137L reverse 
signaling. This protein has experimental merits because it can 
initiate the intracellular CD137L signaling pathway without in-
terferring  with  interactions  between  CD137  and  CD137L.  It 
would be difficult to discern the in vivo effect of CD137L en-
gagement from that of blocking the CD137 signaling pathway 
if  we  used  CD137-Fc  fusion  protein  or  anti-CD137L  mAbs. 
Previous studies have shown that the cytoplasmic domain of 
CTLA-4 fused with PTD of human transcriptional factor Hph-1 
is potent in inhibiting the activity of T cells (24,25). Cytoplas-
m i c  d o m a i n s  o f  c e l l  s u r f a c e  m o l e c u l e s  f u s e d  t o  P T D  a r e  a 
simple  way  to  stimulate  intracellular  signaling  pathways.
    Recent studies suggest that CD137/CD137L interactions may 
participate  in  multiple  stages  of  inflammation  (26).  The 
CD137L reverse signaling transduction pathway in APCs such 
as macrophages and dendritic cells is thought to be essential 
in the amplification loop for inflammation, since they can be 
activated  by  CD137L  engagement  to  secrete  cytokines  and 
chemokines  (4,10).  CD137  and  CD137L  signals  also  play  a 
role in inflammation of non-hematopoietic cells such as endo-
thelial  cells  (15)  and  epithelia l  c e l l s  ( m a n u s c r i p t  i n  s u b -
mission).  CD137  and  CD137L  signals  thus  appear  to  have 
broad control over inflammation, a conclusion also supported 
by the CD137L-mediated control of myelopoiesis (20), which 
may reflect the need for sufficient numbers of inflammatory 
cells  during  acute  inflammation. 
    In TAT-CD137Lct-stimulated macrophages, phosphorylation 
of Erk, p38, and Jnk was induced rapidly and inhibition of 
their phosphorylation reduced IL-6 and TNF-α production. 
Since TAT-CD137Lct did not induce NF-κB activation, early 
activation of the CD137L signaling may result in secretion of 
stored IL-6 and TNF-α. Since CD137Lct increased mRNA lev-
els of IL-6 and TNF-α at 4 and 12 h after its treatment, we 
cannot exclude the possibility that CD137Lct activated NF-κB 
to elevate transcription for IL-6 and TNF-α. We found that 
CD137Lct also activated transcription factors CREB and C/EBP 
at 8 and 12 h after its treatment. It is presumable that activa-
tion  of  these  transcription  factors  is  required  for  late  pro-
duction of IL-6 and TNF-α in macrophages. Interestingly, cell 
surface  CD137L  promotes  sustained  production  of  TNF-α 
through activation of CREB and C/EBP in macrophages in re-
sponse  to  TLR  signals  (19).  Taken  together,  it  seems  that 
CD137L signals regulate proinflammatory cytokine production 
in  macrophages  in  a  tidal  fashion.Triggering of CD137L Signaling Using Transduced CD137L Protein
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